Review supports post-PCI use of dual antiplatelet therapy

07/10/2013 | Healio

A data review found dual antiplatelet therapy is the mainstay treatment for reducing cardiovascular risks after percutaneous coronary intervention, according to researchers from the University of Texas Southwestern Medical Center. The study, published in the Journal of the American Medical Association, recommended the low-dose aspirin component be continued indefinitely and a P2Y12 inhibitor should be prescribed for 12 months, unless patients are at high risk for bleeding.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID